Skip to main content
main-content
Erschienen in: InFo Hämatologie + Onkologie 7-8/2022

28.07.2022 | Pleuramesotheliome | Zertifizierte Fortbildung

Brustfellkrebs

Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms

verfasst von: Dr. med. Dominik Valentin Flury, Prof. Dr. med. Gregor J. Kocher

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 7-8/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Das Pleuramesotheliom ist eine seltene Erkrankung des Brust- und Lungenfells mit schlechter Prognose. Lesen Sie in der folgenden Übersicht, wann an diese Erkrankung gedacht werden soll, wann Abklärungsbedarf besteht und wie, basierend auf den aktuellen Guidelines, Diagnostik-, Staging- sowie Behandlungsstrategien aussehen.
Literatur
1.
Zurück zum Zitat Alpert N et al. Epidemiology of mesothelioma in the 21 st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28-S38 Alpert N et al. Epidemiology of mesothelioma in the 21 st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28-S38
2.
Zurück zum Zitat WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon (France): International Agency for Research on Cancer; 2021:200-2019 WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon (France): International Agency for Research on Cancer; 2021:200-2019
3.
Zurück zum Zitat Popat S et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(*). Ann Oncol. 2022;33(2):129-42 Popat S et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(*). Ann Oncol. 2022;33(2):129-42
4.
Zurück zum Zitat Kazan-Allen L. Current Asbestos Bans; www.ibasecretariat.org/alpha_ban_list.php abgerufen am 4. Juli 2022 Kazan-Allen L. Current Asbestos Bans; www.ibasecretariat.org/alpha_ban_list.php abgerufen am 4. Juli 2022
5.
Zurück zum Zitat Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24(135):115-31 Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24(135):115-31
6.
Zurück zum Zitat Odgerel CO et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74(12):851-8 Odgerel CO et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74(12):851-8
7.
Zurück zum Zitat Bianchi C, Bianchi T. Global mesothelioma epidemic: Trend and features. Indian J Occup Environ Med. 2014;18(2):82-8 Bianchi C, Bianchi T. Global mesothelioma epidemic: Trend and features. Indian J Occup Environ Med. 2014;18(2):82-8
8.
Zurück zum Zitat Delgermaa V et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716-24, 724A-724C Delgermaa V et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716-24, 724A-724C
9.
Zurück zum Zitat Scherpereel A et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953 Scherpereel A et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953
10.
Zurück zum Zitat NCCN Guidelines®. Malignant Pleural Mesothelioma, Version 1.2022; www.nccn.org/guidelines/guidelines abgerufen am 4. Juli 2022 NCCN Guidelines®. Malignant Pleural Mesothelioma, Version 1.2022; www.nccn.org/guidelines/guidelines abgerufen am 4. Juli 2022
11.
Zurück zum Zitat Woolhouse I et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5(1):e000266 Woolhouse I et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5(1):e000266
12.
Zurück zum Zitat Schumann SO et al. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 2021;13(4):2510-23 Schumann SO et al. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 2021;13(4):2510-23
13.
Zurück zum Zitat Aigner C et al. [The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma - An Expert Consensus Paper]. Pneumologie. 2021;75(10):776-94 Aigner C et al. [The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma - An Expert Consensus Paper]. Pneumologie. 2021;75(10):776-94
14.
Zurück zum Zitat Carbone M et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402-29 Carbone M et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402-29
15.
Zurück zum Zitat Sugarbaker DJ et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2011;40(2):298-303 Sugarbaker DJ et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2011;40(2):298-303
16.
Zurück zum Zitat Kindler HL et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343-73 Kindler HL et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343-73
17.
Zurück zum Zitat Tossavainen A. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-6 Tossavainen A. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-6
18.
Zurück zum Zitat National Toxicology Program, Department of Health and Human Services. Report on Carcinogens, Fifteenth Edition, Asbestos, CAS No. 1332-21-4; https://​ntp.​niehs.​nih.​gov/​ntp/​roc/​content/​profiles/​asbestos.​pdf abgerufen am 4. Juli 2022 National Toxicology Program, Department of Health and Human Services. Report on Carcinogens, Fifteenth Edition, Asbestos, CAS No. 1332-21-4; https://​ntp.​niehs.​nih.​gov/​ntp/​roc/​content/​profiles/​asbestos.​pdf abgerufen am 4. Juli 2022
19.
Zurück zum Zitat Pairon JC et al. Pleural plaques and the risk of pleural mesothelioma. J Natl Cancer. Inst 2013; 105(4):293-301 Pairon JC et al. Pleural plaques and the risk of pleural mesothelioma. J Natl Cancer. Inst 2013; 105(4):293-301
20.
Zurück zum Zitat Maxim LD et al. Are pleural plaques an appropriate endpoint for risk analyses? Inhal Toxicol. 2015;27(7):321-34 Maxim LD et al. Are pleural plaques an appropriate endpoint for risk analyses? Inhal Toxicol. 2015;27(7):321-34
21.
Zurück zum Zitat Ameille J et al. Asbestos-related cancer risk in patients with asbestosis or pleural plaques. Rev Mal Respir. 2011;28(6):e11-17 Ameille J et al. Asbestos-related cancer risk in patients with asbestosis or pleural plaques. Rev Mal Respir. 2011;28(6):e11-17
22.
Zurück zum Zitat Kirkham TL et al. Surveillance of mesothelioma and workers' compensation in British Columbia, Canada. Occup Environ Med. 2011;68(1):30-5 Kirkham TL et al. Surveillance of mesothelioma and workers' compensation in British Columbia, Canada. Occup Environ Med. 2011;68(1):30-5
23.
Zurück zum Zitat Chamming's S et al. Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme. Am J Ind Med. 2013;56(2):146-54 Chamming's S et al. Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme. Am J Ind Med. 2013;56(2):146-54
24.
Zurück zum Zitat García-Gómez M et al. Asbestos-related occupational cancers compensated under the Spanish National Insurance System, 1978-2011. Int J Occup Environ Health. 2015; 21(1):31-9 García-Gómez M et al. Asbestos-related occupational cancers compensated under the Spanish National Insurance System, 1978-2011. Int J Occup Environ Health. 2015; 21(1):31-9
25.
Zurück zum Zitat Marinaccio A et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer. 2012;130(9):2146-54 Marinaccio A et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer. 2012;130(9):2146-54
26.
Zurück zum Zitat Park EK et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4):514-8 Park EK et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4):514-8
27.
Zurück zum Zitat Stayner L et al. The Worldwide Pandemic of Asbestos-Related Diseases. Annu Rev Public Health. 2013;34:205-16 Stayner L et al. The Worldwide Pandemic of Asbestos-Related Diseases. Annu Rev Public Health. 2013;34:205-16
28.
Zurück zum Zitat Peto J et al. The European mesothelioma epidemic. Br J Cancer. 1999;79(3-4):666-72 Peto J et al. The European mesothelioma epidemic. Br J Cancer. 1999;79(3-4):666-72
29.
Zurück zum Zitat Vivero M et al. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Mod Pathol. 2018;31(1):122-31 Vivero M et al. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Mod Pathol. 2018;31(1):122-31
30.
Zurück zum Zitat Cavazza A et al. Post-irradiation malignant mesothelioma. Cancer. 1996;77(7):1379-85 Cavazza A et al. Post-irradiation malignant mesothelioma. Cancer. 1996;77(7):1379-85
31.
Zurück zum Zitat Teta MJ et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109(7):1432-8 Teta MJ et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109(7):1432-8
32.
Zurück zum Zitat Chirieac LR et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013;31(36):4544-9 Chirieac LR et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013;31(36):4544-9
33.
Zurück zum Zitat Witherby SM et al. Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer. 2007;57(3):410-3 Witherby SM et al. Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer. 2007;57(3):410-3
34.
Zurück zum Zitat Peterson JT Jr et al. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984; 54(5):951-60. Peterson JT Jr et al. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984; 54(5):951-60.
35.
Zurück zum Zitat Farioli A et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med. 2016;5(5):950-9 Farioli A et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med. 2016;5(5):950-9
36.
Zurück zum Zitat Carbone M et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016;11(8):1246-62 Carbone M et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016;11(8):1246-62
37.
Zurück zum Zitat Righi L et al. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. J Thorac Oncol. 2016;11(11):2006-17 Righi L et al. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. J Thorac Oncol. 2016;11(11):2006-17
38.
Zurück zum Zitat Baumann F et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76-81 Baumann F et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76-81
39.
Zurück zum Zitat Carbone M et al. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153-9 Carbone M et al. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153-9
40.
Zurück zum Zitat American Cancer Society. Cancer Facts & Figures. 2017. Special Section - Rare Cancers in Adults; https://​tinyurl.​com/​yb4joe3c abgerufen am 4. Juli 2022 American Cancer Society. Cancer Facts & Figures. 2017. Special Section - Rare Cancers in Adults; https://​tinyurl.​com/​yb4joe3c abgerufen am 4. Juli 2022
41.
Zurück zum Zitat Musk AW et al. Predicting survival in malignant mesothelioma. Eur Respir J. 2011;38(6):1420-4 Musk AW et al. Predicting survival in malignant mesothelioma. Eur Respir J. 2011;38(6):1420-4
42.
Zurück zum Zitat Meyerhoff RR et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32 Meyerhoff RR et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32
43.
Zurück zum Zitat Linton A et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111(9):1860-9 Linton A et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111(9):1860-9
44.
Zurück zum Zitat Mazurek JM et al. Malignant Mesothelioma Mortality - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214-8 Mazurek JM et al. Malignant Mesothelioma Mortality - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214-8
45.
Zurück zum Zitat van Meerbeeck JP et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78(2):92-111 van Meerbeeck JP et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78(2):92-111
46.
Zurück zum Zitat Jaklitsch MT et al. Treatment of malignant mesothelioma. World J Surg. 2001;25(2):210-7 Jaklitsch MT et al. Treatment of malignant mesothelioma. World J Surg. 2001;25(2):210-7
47.
Zurück zum Zitat Husain AN et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142(1):89-108 Husain AN et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142(1):89-108
48.
Zurück zum Zitat Marchevsky AM et al. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol. 2017;67:160-8 Marchevsky AM et al. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol. 2017;67:160-8
49.
Zurück zum Zitat Arif Q, Husain AN. Malignant Mesothelioma Diagnosis. Arch Pathol Lab Med. 2015;139(8):978-80 Arif Q, Husain AN. Malignant Mesothelioma Diagnosis. Arch Pathol Lab Med. 2015;139(8):978-80
50.
Zurück zum Zitat Wang ZJ et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24(1):105-19 Wang ZJ et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24(1):105-19
51.
Zurück zum Zitat Paintal A et al. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol. 2013;121(12):703-7 Paintal A et al. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol. 2013;121(12):703-7
52.
Zurück zum Zitat Hjerpe A et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta Cytol. 2015;59(1):2-16 Hjerpe A et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta Cytol. 2015;59(1):2-16
53.
Zurück zum Zitat Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136(3):888-96 Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136(3):888-96
54.
Zurück zum Zitat Henderson DW et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66(10):847-53 Henderson DW et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66(10):847-53
55.
Zurück zum Zitat Alì G et al. The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. J Thorac Dis. 2018;10(Suppl_2):S276-s284 Alì G et al. The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. J Thorac Dis. 2018;10(Suppl_2):S276-s284
56.
Zurück zum Zitat Nicholson AG et al. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020;15(1):29-49 Nicholson AG et al. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020;15(1):29-49
57.
Zurück zum Zitat Zhang YZ et al. Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases. 2020;44(3):347-56 Zhang YZ et al. Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases. 2020;44(3):347-56
58.
Zurück zum Zitat Bhatnagar R et al. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. N Engl J Med. 2018;378(14):1313-22 Bhatnagar R et al. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. N Engl J Med. 2018;378(14):1313-22
59.
Zurück zum Zitat Feller-Kopman D, Light R. Pleural Disease. N Engl J Med. 2018;378(18):1754 Feller-Kopman D, Light R. Pleural Disease. N Engl J Med. 2018;378(18):1754
60.
Zurück zum Zitat Zahid I et al. What is the best treatment for malignant pleural effusions? Interact Cardiovasc Thorac Surg. 2011;12(5):818-23 Zahid I et al. What is the best treatment for malignant pleural effusions? Interact Cardiovasc Thorac Surg. 2011;12(5):818-23
61.
Zurück zum Zitat Schneider T et al. Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg. 2009;57(1):42-6 Schneider T et al. Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg. 2009;57(1):42-6
62.
Zurück zum Zitat Roberts HC et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol. 2009;4(5):620-8 Roberts HC et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol. 2009;4(5):620-8
63.
Zurück zum Zitat van Meerbeeck JP, Hillerdal G. Screening for mesothelioma: more harm than good? Am J Respir Crit Care Med. 2008;178(8):781-2 van Meerbeeck JP, Hillerdal G. Screening for mesothelioma: more harm than good? Am J Respir Crit Care Med. 2008;178(8):781-2
64.
Zurück zum Zitat Johnen G et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 2017;17(1):386 Johnen G et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 2017;17(1):386
65.
Zurück zum Zitat Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):97-104 Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):97-104
66.
Zurück zum Zitat Casjens S et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study. BMJ Open. 2017;7(10):e017104 Casjens S et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study. BMJ Open. 2017;7(10):e017104
67.
Zurück zum Zitat Felten MK et al. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health. 2014;87(2):195-204 Felten MK et al. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health. 2014;87(2):195-204
68.
Zurück zum Zitat Marchevsky AM et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol. 2020;33(2):281-96 Marchevsky AM et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol. 2020;33(2):281-96
69.
Zurück zum Zitat Chirieac LR et al. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer. 2019;125(23):4164-71 Chirieac LR et al. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer. 2019;125(23):4164-71
70.
Zurück zum Zitat Pilling J et al. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg. 2010;58(4):215-9 Pilling J et al. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg. 2010;58(4):215-9
71.
Zurück zum Zitat Ahmadzadehfar H et al. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer. 2007;58(3):418-21 Ahmadzadehfar H et al. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer. 2007;58(3):418-21
72.
Zurück zum Zitat Nguyen NC et al. F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med. 2009;34(12):886-90 Nguyen NC et al. F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med. 2009;34(12):886-90
73.
Zurück zum Zitat Berzenji L et al. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543-9 Berzenji L et al. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543-9
74.
Zurück zum Zitat Nowak AK et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2089-99 Nowak AK et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2089-99
75.
Zurück zum Zitat Rusch VW et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631-9 Rusch VW et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631-9
76.
Zurück zum Zitat Pass HI et al. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014;9(6):856-64 Pass HI et al. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014;9(6):856-64
77.
Zurück zum Zitat Brims FJ et al. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. J Thorac Oncol. 2016;11(4):573-82 Brims FJ et al. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. J Thorac Oncol. 2016;11(4):573-82
78.
Zurück zum Zitat Opitz I et al. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience. J Thorac Oncol. 2015;10(11):1634-41 Opitz I et al. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience. J Thorac Oncol. 2015;10(11):1634-41
79.
Zurück zum Zitat de Perrot M et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413-8 de Perrot M et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413-8
80.
Zurück zum Zitat Rusch VW et al. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016;102(4):1059-66 Rusch VW et al. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016;102(4):1059-66
81.
Zurück zum Zitat Herndon JE et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723-31 Herndon JE et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723-31
82.
Zurück zum Zitat Curran D et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145-52 Curran D et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145-52
83.
Zurück zum Zitat Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28 Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28
84.
Zurück zum Zitat Popat S et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734-45 Popat S et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734-45
85.
Zurück zum Zitat Krug LM et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007-13 Krug LM et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007-13
86.
Zurück zum Zitat Thieke C et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015;10:267 Thieke C et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015;10:267
87.
Zurück zum Zitat Abdel-Rahman O et al. Radical multimodality therapy for malignant pleural mesothelioma. Cochrane Database Syst Rev. 2018;1(1):Cd012605 Abdel-Rahman O et al. Radical multimodality therapy for malignant pleural mesothelioma. Cochrane Database Syst Rev. 2018;1(1):Cd012605
88.
Zurück zum Zitat De Bondt C et al. Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations. Transl Lung Cancer Res. 2018;7(5):562-73 De Bondt C et al. Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations. Transl Lung Cancer Res. 2018;7(5):562-73
89.
Zurück zum Zitat Bueno R, Opitz I. Surgery in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(11):1638-54 Bueno R, Opitz I. Surgery in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(11):1638-54
90.
Zurück zum Zitat Bölükbas S et al. Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections. Lung Cancer. 2013; 81(2):241-6 Bölükbas S et al. Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections. Lung Cancer. 2013; 81(2):241-6
91.
Zurück zum Zitat Rusch V et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145(4):909-10 Rusch V et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145(4):909-10
92.
Zurück zum Zitat Treasure T et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763-72 Treasure T et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763-72
93.
Zurück zum Zitat Flores RM et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620-6, 626.e621-623 Flores RM et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620-6, 626.e621-623
94.
Zurück zum Zitat Cao C et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240-5 Cao C et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240-5
95.
Zurück zum Zitat Spaggiari L et al. Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg. 2014;97(6):1859-65 Spaggiari L et al. Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg. 2014;97(6):1859-65
96.
Zurück zum Zitat Hasani A et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol. 2009; 4(8):1010-6 Hasani A et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol. 2009; 4(8):1010-6
97.
Zurück zum Zitat Bölükbas S et al. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer. 2011;71(1):75-81 Bölükbas S et al. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer. 2011;71(1):75-81
98.
Zurück zum Zitat Gupta V et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol. 2009;4(6): 746-50 Gupta V et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol. 2009;4(6): 746-50
99.
Zurück zum Zitat Flores RM et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010;5(10):1649-54 Flores RM et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010;5(10):1649-54
100.
Zurück zum Zitat Baldini EH et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63(2):334-8 Baldini EH et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63(2):334-8
101.
Zurück zum Zitat Taioli E et al. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99(2):472-80 Taioli E et al. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99(2):472-80
102.
Zurück zum Zitat Magouliotis DE et al. Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma. Gen Thorac Cardiovasc Surg. 2019;67(3):312-20 Magouliotis DE et al. Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma. Gen Thorac Cardiovasc Surg. 2019;67(3):312-20
103.
Zurück zum Zitat Schipper PH et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg. 2008;85(1):257-64; discussion 264 Schipper PH et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg. 2008;85(1):257-64; discussion 264
104.
Zurück zum Zitat Nakas A et al. Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2012;41(5):1031-6 Nakas A et al. Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2012;41(5):1031-6
105.
Zurück zum Zitat Schwartz RM et al. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer. 2018;18(1):1188 Schwartz RM et al. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer. 2018;18(1):1188
106.
Zurück zum Zitat Yan TD et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg. 2009;138(3):619-24 Yan TD et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg. 2009;138(3):619-24
107.
Zurück zum Zitat Sugarbaker DJ et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004; 128(1):138-46 Sugarbaker DJ et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004; 128(1):138-46
108.
Zurück zum Zitat Lauk O et al. Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. Ann Thorac Surg. 2014;98(5):1748-54 Lauk O et al. Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. Ann Thorac Surg. 2014;98(5):1748-54
109.
Zurück zum Zitat Bovolato P et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9(3):390-6 Bovolato P et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9(3):390-6
110.
Zurück zum Zitat Kucukoner M et al. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey. J BUON 2014;19(1): 164-70 Kucukoner M et al. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey. J BUON 2014;19(1): 164-70
111.
Zurück zum Zitat Sugarbaker DJ et al. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg. 2014;260(4):577-80; discussion 580-2 Sugarbaker DJ et al. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg. 2014;260(4):577-80; discussion 580-2
112.
Zurück zum Zitat Saddoughi SA et al. National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study. Ann Thorac Surg. 2018;105(2):432-7 Saddoughi SA et al. National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study. Ann Thorac Surg. 2018;105(2):432-7
113.
Zurück zum Zitat Rosskamp M et al. Real-life treatment practice for malignant pleural mesothelioma in Belgium. Lung Cancer. 2018;125:258-64 Rosskamp M et al. Real-life treatment practice for malignant pleural mesothelioma in Belgium. Lung Cancer. 2018;125:258-64
114.
Zurück zum Zitat Nelson DB et al. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017;35(29):3354-62 Nelson DB et al. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017;35(29):3354-62
115.
Zurück zum Zitat Beebe-Dimmer JL et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743-50 Beebe-Dimmer JL et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743-50
116.
Zurück zum Zitat Zhao ZY et al. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget. 2017;8(59):100640-7 Zhao ZY et al. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget. 2017;8(59):100640-7
117.
Zurück zum Zitat de Bree E et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest. 2002;121(2):480-7 de Bree E et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest. 2002;121(2):480-7
118.
Zurück zum Zitat Lang-Lazdunski L et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015;149(2):558-65; discussion 565-6 Lang-Lazdunski L et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015;149(2):558-65; discussion 565-6
119.
Zurück zum Zitat Sugarbaker DJ et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145(4):955-63 Sugarbaker DJ et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145(4):955-63
120.
Zurück zum Zitat Ried M et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43(4):801-7 Ried M et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43(4):801-7
121.
Zurück zum Zitat Lang-Lazdunski L et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011;6(10):1746-52 Lang-Lazdunski L et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011;6(10):1746-52
122.
Zurück zum Zitat Boyer MJ et al. O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer. 2003;41(Suppl_2):S19 Boyer MJ et al. O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer. 2003;41(Suppl_2):S19
123.
Zurück zum Zitat Vogelzang NJ et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44 Vogelzang NJ et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44
124.
Zurück zum Zitat van Meerbeeck JP et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881-9 van Meerbeeck JP et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881-9
125.
Zurück zum Zitat Bottomley A et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006;24(9):1435-42 Bottomley A et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006;24(9):1435-42
126.
Zurück zum Zitat Byrne MJ et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17(1):25-30 Byrne MJ et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17(1):25-30
127.
Zurück zum Zitat Nowak AK et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87(5):491-6 Nowak AK et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87(5):491-6
128.
Zurück zum Zitat van Haarst JM et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86(3):342-5 van Haarst JM et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86(3):342-5
129.
Zurück zum Zitat Arrieta O et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014;73(5):975-82 Arrieta O et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014;73(5):975-82
130.
Zurück zum Zitat Zalcman G et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405-14 Zalcman G et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405-14
131.
Zurück zum Zitat Srour SA, Stoner JA. Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis. J Clin Oncol. 2016;34(15_suppl):8554-4 Srour SA, Stoner JA. Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis. J Clin Oncol. 2016;34(15_suppl):8554-4
132.
Zurück zum Zitat Ceresoli GL et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443-8 Ceresoli GL et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443-8
133.
Zurück zum Zitat Santoro A et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756-63 Santoro A et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756-63
134.
Zurück zum Zitat Katirtzoglou N et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer. 2010;11(1):30-5 Katirtzoglou N et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer. 2010;11(1):30-5
135.
Zurück zum Zitat Castagneto B et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370-3 Castagneto B et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370-3
136.
Zurück zum Zitat Ceresoli GL et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109(3):552-8 Ceresoli GL et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109(3):552-8
137.
Zurück zum Zitat Scagliotti GV et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21(8):1556-61 Scagliotti GV et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21(8):1556-61
138.
Zurück zum Zitat Taylor P et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008;3(7):764-71 Taylor P et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008;3(7):764-71
139.
Zurück zum Zitat Muers MF et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371(9625):1685-94 Muers MF et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371(9625):1685-94
140.
Zurück zum Zitat Baas P et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-86 Baas P et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-86
141.
Zurück zum Zitat Peters S et al. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. Ann Oncol. 2021;32(Suppl_5):S1341-S1342 Peters S et al. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. Ann Oncol. 2021;32(Suppl_5):S1341-S1342
142.
Zurück zum Zitat Nishino M et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2(12):1607-16 Nishino M et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2(12):1607-16
143.
Zurück zum Zitat Naidoo J et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017;35(7):709-17 Naidoo J et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017;35(7):709-17
144.
Zurück zum Zitat Sgambato A et al. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Curr Drug Saf. 2016;11(1):62-8 Sgambato A et al. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Curr Drug Saf. 2016;11(1):62-8
145.
Zurück zum Zitat Shah R et al. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Clin Lung Cancer. 2021;22(2):142-6 Shah R et al. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Clin Lung Cancer. 2021;22(2):142-6
146.
Zurück zum Zitat de Gooijer CJ et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med. 2021;9(6):585-92 de Gooijer CJ et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med. 2021;9(6):585-92
147.
Zurück zum Zitat Fennell DA et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019;37(10):790-8 Fennell DA et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019;37(10):790-8
148.
Zurück zum Zitat Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13(7):e301-310 Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13(7):e301-310
149.
Zurück zum Zitat Abdel-Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med. 2015;9(5):533-49 Abdel-Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med. 2015;9(5):533-49
150.
Zurück zum Zitat Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012;10(1):42-7 Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012;10(1):42-7
151.
Zurück zum Zitat Ceresoli GL et al. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev. 2010;36(1):24-32 Ceresoli GL et al. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev. 2010;36(1):24-32
152.
Zurück zum Zitat Bearz A et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes. 2012;5:482 Bearz A et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes. 2012;5:482
153.
Zurück zum Zitat Zucali PA et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75(3):360-7 Zucali PA et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75(3):360-7
154.
Zurück zum Zitat Ceresoli GL et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72(1):73-7 Ceresoli GL et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72(1):73-7
155.
Zurück zum Zitat Petrelli F et al. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respir Med. 2018;141:72-80 Petrelli F et al. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respir Med. 2018;141:72-80
156.
Zurück zum Zitat Fennell DA et al. A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. J Clin Oncol. 2021;39(15_suppl):8507-8507 Fennell DA et al. A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. J Clin Oncol. 2021;39(15_suppl):8507-8507
157.
Zurück zum Zitat Zucali PA et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2014; 84(3):265-70 Zucali PA et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2014; 84(3):265-70
158.
Zurück zum Zitat Stebbing J et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009; 63(1):94-7 Stebbing J et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009; 63(1):94-7
159.
Zurück zum Zitat Steele JP et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18(23):3912-7 Steele JP et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18(23):3912-7
160.
Zurück zum Zitat Manegold C et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16(6):923-7 Manegold C et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16(6):923-7
161.
Zurück zum Zitat van Meerbeeck JP et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999;85(12):2577-82 van Meerbeeck JP et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999;85(12):2577-82
162.
Zurück zum Zitat Maio M et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261-73 Maio M et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261-73
163.
Zurück zum Zitat Alley EW et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623-30 Alley EW et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623-30
164.
Zurück zum Zitat Hassan R et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(3):351-7 Hassan R et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(3):351-7
165.
Zurück zum Zitat Desai A et al. Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol. 2018;36(15_suppl):8565-65 Desai A et al. Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol. 2018;36(15_suppl):8565-65
166.
Zurück zum Zitat Quispel-Janssen J et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(10):1569-76 Quispel-Janssen J et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(10):1569-76
167.
Zurück zum Zitat Okada M et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485-92 Okada M et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485-92
168.
Zurück zum Zitat Scherpereel A et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239-53 Scherpereel A et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239-53
169.
Zurück zum Zitat Disselhorst MJ et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260-70 Disselhorst MJ et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260-70
170.
Zurück zum Zitat Calabrò L et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451-60 Calabrò L et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451-60
171.
Zurück zum Zitat Pagano M et al. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study. J Clin Oncol. 2020;38(15_suppl):9004-4 Pagano M et al. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study. J Clin Oncol. 2020;38(15_suppl):9004-4
172.
Zurück zum Zitat Fennell DA et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530-40 Fennell DA et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530-40
173.
Zurück zum Zitat Ashton M et al. The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. Radiother Oncol. 2017;125(1):1-12 Ashton M et al. The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. Radiother Oncol. 2017;125(1):1-12
174.
Zurück zum Zitat Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):159-63 Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):159-63
175.
Zurück zum Zitat Gupta V et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63(4):1045-52 Gupta V et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63(4):1045-52
176.
Zurück zum Zitat Krayenbuehl J et al. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys. 2007;69(5):1593-9 Krayenbuehl J et al. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys. 2007;69(5):1593-9
177.
Zurück zum Zitat Rimner A, Rosenzweig KE. Novel radiation therapy approaches in malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1(4):457-61 Rimner A, Rosenzweig KE. Novel radiation therapy approaches in malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1(4):457-61
178.
Zurück zum Zitat Patel PR et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(1):362-8 Patel PR et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(1):362-8
179.
Zurück zum Zitat Rimner A et al. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016;34(23):2761-8 Rimner A et al. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016;34(23):2761-8
180.
Zurück zum Zitat Rice DC et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84(5):1685-92; discussion 1692-83 Rice DC et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84(5):1685-92; discussion 1692-83
181.
Zurück zum Zitat Allen AM et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65(3):640-5 Allen AM et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65(3):640-5
182.
Zurück zum Zitat Rosenzweig KE et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83(4):1278-83 Rosenzweig KE et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83(4):1278-83
183.
Zurück zum Zitat Yorke ED et al. Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys. 2017;99(1):61-9 Yorke ED et al. Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys. 2017;99(1):61-9
184.
Zurück zum Zitat Rusch VW et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122(4):788-95 Rusch VW et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122(4):788-95
185.
Zurück zum Zitat Yajnik S et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56(5):1319-26 Yajnik S et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56(5):1319-26
186.
Zurück zum Zitat Boutin C et al. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108(3):754-8 Boutin C et al. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108(3):754-8
187.
Zurück zum Zitat Trovo M et al. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2021;109(5):1368-76 Trovo M et al. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2021;109(5):1368-76
188.
Zurück zum Zitat Minatel E et al. OC-0500 Radical Hemi-thoracic Radiotherapy vs. Palliative Radiotherapy for Malignant Pleural Mesothelioma. Radiother Oncol. 2019;133(Suppl_1):S257 Minatel E et al. OC-0500 Radical Hemi-thoracic Radiotherapy vs. Palliative Radiotherapy for Malignant Pleural Mesothelioma. Radiother Oncol. 2019;133(Suppl_1):S257
189.
Zurück zum Zitat Minatel E et al. Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. Int J Radiat Oncol Biol Phys. 2015;93(3):606-13 Minatel E et al. Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. Int J Radiat Oncol Biol Phys. 2015;93(3):606-13
190.
Zurück zum Zitat Stahel RA et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651-8 Stahel RA et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651-8
191.
Zurück zum Zitat de Graaf-Strukowska L et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43(3):511-6 de Graaf-Strukowska L et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43(3):511-6
192.
Zurück zum Zitat Di Salvo M et al. Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma. Acta Oncol. 2008;47(6):1094-8 Di Salvo M et al. Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma. Acta Oncol. 2008;47(6):1094-8
193.
Zurück zum Zitat Clive AO et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094-1104 Clive AO et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094-1104
194.
Zurück zum Zitat Stewart SA et al. Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial. PLoS One 2018;13(2):e0190257 Stewart SA et al. Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial. PLoS One 2018;13(2):e0190257
195.
Zurück zum Zitat Bayman N et al. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. J Clin Oncol. 2019;37(14):1200-8 Bayman N et al. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. J Clin Oncol. 2019;37(14):1200-8
196.
Zurück zum Zitat Bydder S et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91(1):9-10 Bydder S et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91(1):9-10
197.
Zurück zum Zitat O'Rourke N et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84(1):18-22 O'Rourke N et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84(1):18-22
198.
Zurück zum Zitat Davies HE et al. Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues. Curr Opin Pulm Med. 2008;14(4):326-30 Davies HE et al. Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues. Curr Opin Pulm Med. 2008;14(4):326-30
199.
Zurück zum Zitat MacLeod N et al. Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. J Thorac Oncol. 2015;10(6):944-50 MacLeod N et al. Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. J Thorac Oncol. 2015;10(6):944-50
200.
Zurück zum Zitat Brims F et al. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74(4):354-61 Brims F et al. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74(4):354-61
201.
Zurück zum Zitat Freeman RK et al. A Propensity-Matched Comparison of Pleurodesis or Tunneled Pleural Catheter for Heart Failure Patients With Recurrent Pleural Effusion. Ann Thorac Surg. 2014;97(6):1872-7 Freeman RK et al. A Propensity-Matched Comparison of Pleurodesis or Tunneled Pleural Catheter for Heart Failure Patients With Recurrent Pleural Effusion. Ann Thorac Surg. 2014;97(6):1872-7
202.
Zurück zum Zitat Muruganandan S et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6(9):671-80 Muruganandan S et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6(9):671-80
203.
Zurück zum Zitat Matthews C et al. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial. BMJ Open Respir Res. 2019;6(1):e000368 Matthews C et al. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial. BMJ Open Respir Res. 2019;6(1):e000368
204.
Zurück zum Zitat Rintoul RC et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118-27 Rintoul RC et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118-27
205.
Zurück zum Zitat Thapa B et al. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. J Thorac Oncol. 2017;12(5):850-9 Thapa B et al. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. J Thorac Oncol. 2017;12(5):850-9
206.
Zurück zum Zitat Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71 Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71
207.
Zurück zum Zitat Rizvi NA et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8 Rizvi NA et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8
208.
Zurück zum Zitat Süveg K et al. Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018;124:12-8 Süveg K et al. Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018;124:12-8
Metadaten
Titel
Brustfellkrebs
Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms
verfasst von
Dr. med. Dominik Valentin Flury
Prof. Dr. med. Gregor J. Kocher
Publikationsdatum
28.07.2022